Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.

Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S, Chang R, Friedlander P, Saenger YM.

Melanoma Res. 2013 Feb;23(1):47-54. doi: 10.1097/CMR.0b013e32835c7e68.

PMID:
23262440
2.

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.

Yamazaki N, Kiyohara Y, Uhara H, Fukushima S, Uchi H, Shibagaki N, Tsutsumida A, Yoshikawa S, Okuyama R, Ito Y, Tokudome T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):997-1004. doi: 10.1007/s00280-015-2873-x. Epub 2015 Sep 26.

3.

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.

Yamazaki N, Uhara H, Fukushima S, Uchi H, Shibagaki N, Kiyohara Y, Tsutsumida A, Namikawa K, Okuyama R, Otsuka Y, Tokudome T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25.

4.

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.

Lipson EJ, Drake CG.

Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7. Review.

5.

Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.

Woźniak S, Mackiewicz-Wysocka M, Krokowicz Ł, Kwinta Ł, Mackiewicz J.

Oncol Res Treat. 2015;38(3):105-8. doi: 10.1159/000377650. Epub 2015 Feb 20.

PMID:
25792081
6.

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.

7.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

8.

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.

Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kämpgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, Assi Z, Garbe C, Schadendorf D.

J Transl Med. 2015 Nov 6;13:351. doi: 10.1186/s12967-015-0716-5.

9.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ.

Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11.

10.

Management of immune-related adverse events and kinetics of response with ipilimumab.

Weber JS, Kähler KC, Hauschild A.

J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. Review.

PMID:
22614989
11.

Ipilimumab: a novel treatment for metastatic melanoma.

Culver ME, Gatesman ML, Mancl EE, Lowe DK.

Ann Pharmacother. 2011 Apr;45(4):510-9. doi: 10.1345/aph.1P651. Epub 2011 Apr 19. Review.

PMID:
21505108
12.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
13.

Ipilimumab-induced toxicities and the gastroenterologist.

Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, Shackel N.

J Gastroenterol Hepatol. 2015 Apr;30(4):657-66. doi: 10.1111/jgh.12888. Review.

PMID:
25641691
14.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

15.

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA.

Endocr Relat Cancer. 2014 Mar 7;21(2):371-81. doi: 10.1530/ERC-13-0499. Print 2014 Apr. Review.

16.

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD.

Ann Oncol. 2014 Nov;25(11):2277-84. doi: 10.1093/annonc/mdu441. Epub 2014 Sep 10.

17.

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D.

PLoS One. 2015 Mar 11;10(3):e0118564. doi: 10.1371/journal.pone.0118564. eCollection 2015.

18.

Ipilimumab-induced colitis in patients with metastatic melanoma.

De Felice KM, Gupta A, Rakshit S, Khanna S, Kottschade LA, Finnes HD, Papadakis KA, Loftus EV Jr, Raffals LE, Markovic SN.

Melanoma Res. 2015 Aug;25(4):321-7. doi: 10.1097/CMR.0000000000000165.

PMID:
25933207
19.

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M.

Cancer Immunol Immunother. 2012 Jan;61(1):41-8. doi: 10.1007/s00262-011-1089-0. Epub 2011 Aug 11.

PMID:
21833591
20.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211

Supplemental Content

Support Center